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Inﬂammatory bowel disease (IBD) is a disease that affects the intestinal tract via an inﬂam-
matory process. Patients who suffer from IBD often have diseases that affect multiple
other organ systems as well. These are called extraintestinal manifestations and can be
just as, if not more debilitating than the intestinal inﬂammation itself. The skin is one of
the most commonly affected organ systems in patients who suffer from IBD.The scientiﬁc
literature suggests that a disturbance of the equilibrium between host defense and toler-
ance, and the subsequent over-activity of certain immune pathways are responsible for the
cutaneous disorders seen so frequently in IBD patients. The purpose of this review article
is to give an overview of the types of skin diseases that are typically seenwith IBD and their
respective pathogenesis, proposed mechanisms, and treatments. These cutaneous disor-
ders can manifest as metastatic lesions, reactive processes to the intestinal inﬂammation,
complications of IBD itself, or side effects from IBD treatments; these can be associated
with IBD via genetic linkage, common autoimmune processes, or other mechanisms that
will be discussed in this article. Ultimately, it is important for healthcare providers to under-
stand that skin manifestations should always be checked and evaluated for in patients with
IBD. Furthermore, skin disorders can predate gastrointestinal symptoms and thus may
serve as important clinical indicators leading physicians to earlier diagnosis of IBD.
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INTRODUCTION
OVERVIEW
Inﬂammatory bowel disease (IBD) is an idiopathic and inﬂamma-
tory disease of the intestinal tract. The two major types of IBD
are ulcerative colitis (UC) and Crohn’s disease (CD). As the name
implies, UC is limited to the colon and/or rectum (normally con-
tinuous lesions in the rectum and colon), and affects only the
inner lining (mucosal and submucosal layers) of the gut. In con-
trast, CD can affect any part of the gut from mouth to anus as
non-continuous or skip lesions (a majority of cases start in the
terminal ileum), and affect the whole thickness (transmural) of
the bowel wall.
Up to 40% of IBD patients may be complicated by extraintesti-
nal manifestations (EIMs) and in some large series of studies, the
prevalence of EIMs is higher in CD compared to UC (Vind et al.,
2006;Vavricka et al., 2011). In a large cohort study of 950 patients,
EIMs were identiﬁed in 43% of 580 patients with CD and 31%
of 370 patients with UC (Vavricka et al., 2011). Multiple organ
systems and almost every organ system may be affected in IBD,
including the musculoskeletal system, skin, eyes, hepatobiliary
system, lungs, kidneys, immunologic or hematologic system, and
cardiovascular system (Williams et al., 2008; Vavricka et al., 2011).
Themost common EIMs of IBD are peripheral arthritis, aphthous
stomatitis, uveitis, and erythema nodosum (EN; Vavricka et al.,
2011). Among the organ systems involved, the skin is one of the
most commonly affected organ systems. The most common skin
or mucocutaneous lesions associated with IBD are EN, pyoderma
gangrenosum (PG), and aphthous stomatitis (oral ulceration;
Rothfuss et al., 2006; Larsen et al., 2010). Aphthous stomatitis or
aphthae are the most common complication of the oral mucosa,
while ﬁssure and ﬁstulae are most common complication of the
perianal mucosa. EN and PG are immunoreactive in nature as a
result of the underlying IBD disease. In addition, skin lesions in
IBD patients can also be caused by nutritional deﬁciencies, such as
pellagra and cheilitis. Medication side effects, such as cushingoid
features from steroid usage or drug eruptions from immunosup-
pressant medications have also been noted. Other skin disorders
such psoriasis and vitiligo have also been associated with IBD
(Timani and Mutasim, 2008).
MECHANISMS BETWEEN IBD AND SKIN DISORDERS
Mucosal T-cells are important in maintaining intestinal home-
ostasis, deﬁned as the balance between the mucosal epithelium,
intestinal microbes, and host immune response (van Wijk and
Cheroutre, 2010). Abnormal T-cell response to these microbial
antigens can disrupt this equilibrium and is believed to be the
mechanism that triggers the chronic inﬂammation and exces-
sive secretion of cytokines that lead to the development of IBD
(Izcue et al., 2009; van Wijk and Cheroutre, 2010; Monteleone
et al., 2011). It has been proposed that some EIM’s seen with
IBD manifest also as a result of immune dysregulation result-
ing in a lymphocyte mediated destructive process. Adams and
Eksteen (2006) proposed IBD patients with hepatic EIMs could be
explained by mucosal T-cells in the gut aberrantly traveling to the
liver, becoming exposed to hepatic antigens, and ultimately caus-
ing liver damage. This article suggested that a similar mechanism
could possibly explain the pathogenesis of other EIM’s (including
the skin) in patients with IBD (Adams and Eksteen, 2006).
www.frontiersin.org February 2012 | Volume 3 | Article 13 | 1
Huang et al. IBD skin manifestations
Studies have implicated several immune pathways in cutaneous
disorders of IBD. In addition to the two established effector CD4
T-cells, the Th1 (cell-mediated) and Th2 (humoral), a third novel
T-helper cell has been described. Termed Th17 cells for its ability
to produce interleukin-17 (IL-17), these cells have been described
in various systemic, inﬂammatory, and autoimmune skin disor-
ders including psoriasis, contact or atopic dermatitis, scleroderma,
systemic lupus erythematosus (SLE), Bechet’s disease, and IBD
(Asarch et al., 2008). This discovery brings to light new treatment
targets for dermatologic disorders in the IBD population.
Classically, CD has been considered to be mediated by Th1
pathways with elevated levels of IFN-γ and IL-12. On the other
hand, UC has been associated with Th2 mediated pathways with
elevated levels of IL-5 and IL-13 (van Wijk and Cheroutre, 2010).
However, recent evidence from mouse models challenges these
viewpoints and suggests that IL-23, induced by Th17 produced
cytokines (IL-17 and IL-22, which are present in both CD and
UC), is one of the major players in the pathogenesis of IBD (Hue
et al., 2006). This IL-23 and Th17 pathway has been proposed as a
common pathway of the development of IBD (both CD and UC)
and other autoimmune diseases as well (Ahern et al., 2008; van
Wijk and Cheroutre, 2010; Abraham and Medzhitov, 2011; Lees
et al., 2011). Most recently, high levels of expression of IL-23 was
reported in a difﬁcult to treat PG lesion. Treatment with a mon-
oclonal antibody ustekinumab for 14weeks resulted in marked
suppression of IL-23 expression and clinical resolution of the PG
lesion (Guenova et al., 2011).
CLASSIFICATION
The cutaneous manifestations of IBD have been classiﬁed into the
following categories according to pathogenesis (Table 1; Danese
et al., 2005; Trost andMcDonnell, 2005; Passarini et al., 2007;Mnif
et al., 2010; Levine and Burakoff, 2011):
A. Speciﬁc cutaneous manifestations or granulomatous cuta-
neous lesions with the same histological features as the
underlying bowel disease.
B. Reactive cutaneous manifestation of IBD with immunologi-
cal mechanisms triggered by common antigens shared by gut
bacteria and skin.
C. Cutaneous disorders or dermatosis associated with IBD.
D. Secondary cutaneous manifestations either due to complica-
tions of IBD or adverse effects of IBD treatments.
CUTANEOUS MANIFESTATIONS WITH SAME HISTOLOGICAL
FEATURES AS THE UNDERLYING IBD
CUTANEOUS MANIFESTATIONS
Cutaneous or metastatic CD is a rare complication deﬁned as the
occurrence of speciﬁc granulomatous cutaneous lesions with the
same histopathology (non-caseating granulomaswithmultinucle-
ated giant cells in the dermis surrounded by lymphocytes, plasma
cells, and eosinophils) as the intestinal lesions (Georgiou et al.,
2006). It occurs more frequently in adult females with established
intestinal CD (Georgiou et al., 2006). This disorder presents com-
monly as subcutaneous nodules or non-healing ulcers in the lower
extremities with rare localization to the genital (vulvar or testic-
ular) area; pseudocondyloma mimicking genital warts can also
occur (Georgiou et al., 2006; Larsen et al., 2010). Cutaneous CD
can be divided into two clinical forms: the genital form (56%)
which occurs more in children (characterized by edema, ery-
thema, ﬁssures or ulcers of the labia, scrotum, or penis), and the
non-genital form (44%) which most commonly affects the lower
extremities (38%), abdomen and trunk (24%), upper extremi-
ties (15%), face and lips (11%), and intertriginous areas (8%;
Ploysangam et al., 1997). It seems unrelated to the activity of the
bowel disease or its response to the IBD treatment (Chalvardjian
and Nethercott, 1982; Lebwohl et al., 1984; Lestre et al., 2010).
Various treatment modalities have been tried, such as steroids
(topical, intralesional, or systemic), sulfasalazine, metronidazole,
azathioprine, methotrexate, hyperbaric oxygen, and anti-TNF-α
antibodies (Sarna et al., 2008; Lestre et al., 2010). In cases with
severe cutaneous ulcers unresponsive to medical treatment, sur-
gical resection under oral administration of zinc sulfate may be
indicated (Georgiou et al., 2006).
PERIANAL MANIFESTATIONS
Perianal CD including erythema, abscesses, ulcers, ﬁssures, and ﬁs-
tulas,occur in about 50%of CDpatients at somepoint during their
clinical course (Danese et al., 2005). Perianal ﬁssures and ﬁstulas,
usually one of themost common skin lesions of IBD, occurmainly
inCD (20–60%) and rarely inUC (Roberts andBunker, 1993; Leb-
wohl and Lebwohl, 1998). Perianal ﬁssures and ﬁstula are due to
direct involvement of skin and mucosa via a similar mechanism
as the bowel disease and may antedate the signs and symptoms of
bowel disease by several years (Figure 1; Ploysangam et al., 1997;
Lebwohl and Lebwohl, 1998). Fissures are usually painless and
located posteriorly, whereas ﬁstulas manifest either as a cryptog-
landular infection or as a secondary complication of anal ﬁssures.
Fistulas can be internal or entero-cutaneous and can undermine
ulcers and destroy the anal sphincter (Danese et al., 2005).
The recommended treatment of perianal ﬁssures is topical
application of glyceryl trinitrate (nitroglycerine) ointment and in
some cases this is followed by Botox injections into the affected
anal sphincter area (Jonas andScholeﬁeld,2001). In caseswith only
limited response to these compounds, calciumchannel antagonists
(diltiazem) or lateral internal sphincterotomy may be indicated
(Fleshner et al., 1995; Singh et al., 2009). For perianal ﬁstulas,
combined medical and surgical therapies offer the best chance
for success (Lewis and Maron, 2010). Medical treatments include
antibiotics (metronidazole, ciproﬂoxacin), immunosuppressants
(azathioprine, 6-MP, cyclosporine, and tacrolimus), and inﬂix-
imab (Safar and Sands, 2007; Lewis and Maron, 2010). Surgery
include ﬁstulotomy for low ﬁstulae (below the dentate line),
advance ﬂap or ﬁstula plug for high ﬁstulae (above dentate line),
proctectomy with colostomy for severe perianal disease with rectal
involvement (Georgiou et al., 2006; Safar and Sands, 2007; Lewis
and Maron, 2010).
OROFACIAL MANIFESTATIONS
Orofacial CD may antedate the typical bowel symptoms by sev-
eral months to years. Its presentation and severity do not always
correlate with the activity of the underlying bowel disease. Orofa-
cial involvement occurs in 5–20% of CD patients and can present
as: aphthous stomatitis, pyostomatitis vegetans, angular cheilitis
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Table 1 | Summary table of cutaneous manifestations of IBD.
Cutaneous
manifestation
Presentation Incidence Pathogenesis or proposed mechanism
CD UC
SPECIFIC CUTANEOUS MANIFESTATIONSWITHTHE SAME HISTOLOGICAL FEATURESASTHE UNDERLYING IBD
Orofacial:
aphthous
stomatitis, ulcers
Symptoms: round to oval shaped, can take
2–4weeks to heal and may frequently scar
depending on size
10% 4% CD: non-caseating granuloma with similar mecha-
nism to underlying bowel pathology
Location: buccal mucosa and lips. UC: unclear
Perianal: ﬁssures,
ﬁstulas
Fissures: painless, located posteriorly 50% (≥1
episode)
Rare Direct local involvement of skin and mucosa by
underlying bowel diseaseFistulas: internal or entero-cutaneous, can
destroy the anal sphincter
Metastatic Symptoms: subcutaneous nodules or
non-healing ulcers
Rare Very rare Speciﬁc granulomatous cutaneous lesions with the
same histopathology (non-caseating granulomas
with multinucleated giant cells in the dermis) as the
intestinal lesions
Location: genital (more common in children) vs.
non-genital (more commonly affects lower
extremities, abdomen, and trunk)
Affects: adult/female predilection
REACTIVE CUTANEOUS MANIFESTATIONSWITH IMMUNOLOGICAL MECHANISMS RELATEDTOTHE UNDERLYING IBD
Erythema
nodosum
Symptoms: painful, tender, warm nodules with
a bruise-like appearance
4–15% 3–10% Panniculitis, perivascular deposits of immunoglob-
ulins, and complement suggesting mechanism
related to abnormal immunological response of
common antigens between bowel bacteria and skin
Location: typically lower extremities
Affects: female predilection
Pyoderma
gangrenosum
Symptoms: non-infectious nodules that develop
into deep and painful ulcers. Often debilitating
1–2% 5–12% A type of neutrophilic dermatosis
Location: lower extremities, peristomal lesions Altered immune response (cross-reacting autoanti-
bodies to common antigens in the gut and skin),
over-expression of pro-inﬂammatory cytokines (IL-8,
IL-16, TNF-α), and neutrophil chemotaxis
Affects: female predilection Pathergy: exaggerated response of skin to local
trauma
Sweet’s
syndrome (SS)
Symptoms: fever, peripheral neutrophilia, tender
nodules/papules
Rare UC>CD A type of neutrophilic dermatosis
Location: upper limbs, face, neck. Can be
difﬁcult to distinguish from EN if affecting lower
extremities
Altered immune response (cross-reacting autoanti-
bodies)
Affects: adult/female predilection ANCA, G-CSF, or other cytokines in activation, mat-
uration, and chemotaxis of neutrophils
Bowel-associated
dermatosis–
arthritis
syndrome
(BADAS)
Symptoms: erythematous macules developing
into painful papules and pustules over 1–2 days.
Usually resolve in 1–2weeks, but can recur
every 1–6weeks. Temporally dependent on IBD
activity. Associated with fever, malaise,
abdominal pain, arthralgias
Rare UC>CD A type of neutrophilic dermatosis
Location: upper chest, arms, legs Overgrowth of gut bacteria resulting in production
of antibodies to gut bacteria antigen (peptidoglycan)
which cross-reacts with skin and joints
PDV, PSV, PPV PDV: pustules in skin folds (axillary, inguinal
regions)
Rare UC>CD Unclear, but possible related to cross-reacting anti-
gens between the bowel and skin
PSV: hyperplastic folds of buccal and labial
mucosa that progress to shallow ulcers
PPV: variants of PDV and PSV. speciﬁc marker of
IBD
Affects: adult/Caucasian/male predilection
(Continued)
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Table 1 | Continued
Cutaneous
manifestation
Presentation Incidence Pathogenesis or proposed mechanism
CD UC
Leukocytoclastic
vasculitis
Symptoms: ranges from palpable purpura to
necrotic ulcers. In CD, can occur during
remission or exacerbation. In UC, precedes
onset of bowel disease.
Rare UC>CD Hypersensitivity vasculitis of small vessels due to
deposition of immune complexes
CUTANEOUS DISORDERS OR DERMATOSIS ASSOCIATEDWITH IBD
Psoriasis Symptoms: pruritic and irritated scaly patches.
Can be associated with nail changes, arthritis
11.2% 5.7% Genetic (HLA linkage) or Immunologic relatedmech-
anisms
Location: elbows, knees, trunk, but can occur
anywhere
Secondary
amyloidosis
Symptoms: pruritic rash due to deposits of
amyloid in the skin
0.9% 0.07% Type AA Amyloidosis, reactive systemic amyloidosis
associated with chronic inﬂammation
Vitiligo Symptoms: irregular white patches of skin Rare UC>CD Related to autoimmune or HLA linkagemechanisms
Location: face, elbows, knees, hands, feet,
genitals
Acquired
epidermolysis
bullosa
Symptoms: sub-epidermal blisters of the skin
and mucous membranes
Rare UC>CD Unclear, but related to autoantibodies to type VII
collagen in the skin and gut
SECONDARY CUTANEOUS MANIFESTATIONS EITHER DUETO COMPLICATIONS OF IBD ORADVERSE EFFECTS OF IBDTREATMENTS
Zinc deﬁciency
(acrodermatitis
enteropathica)
Symptoms: erythematous patches and plaques
that progress to crusted vesicles, bullae, or
pustules
40% No
difference
compared
to control
Reduced mucosa availability for absorption and
chronic diarrhea
Location: mouth, anus, limbs, ﬁngers, scalp
Iron deﬁciency
anemia
Symptoms: koilonychias, angular cheilitis, pale
skin
39% 81% Malabsorption of iron and chronic intestinal bleeding
Essential fatty
acid deﬁciency
Symptoms: Xeroderma, dry skin, unspeciﬁc
eczema
CD>UC UC<CD Malabsorption
Corticosteroid
usage
Symptoms: corticosteroid induced acne Common Common Increased sebaceous gland activity
Affects: younger patients
Anti-TNF-αagents Symptoms: anti-TNF α agent induced psoriasis Total of 15
cases
described
Total of
three cases
described
Over-expression of IFN-α causing predisposition to
psoriasis
and ulceration, mucosal nodularity (cobblestoning of the buccal
mucosa), nodules of gingival and alveolar mucosa, and indurated
ﬁssuring of lower lips (Trost and McDonnell, 2005; Georgiou et
al., 2006). Biopsy of the lesions in CD patients, although rarely
required, can reveal non-caseating granulomas similar to bowel
lesions.
Aphthous stomatitis or ulcers, typically seen in the buccal
mucosa and lips, consist of oral ulcers and aremore common inCD
(10%) than UC (4%;Vavricka et al., 2011). Minor aphthous ulcers
are small, shallow, round to oval shaped, have a grayish base, and
canbepainful,but healwithin 2weekswithout scarring (Figure 2).
On the other hand, major recurrent ulcers are larger, can last for
6weeks, and frequently scar (Ship, 1996; Timani and Mutasim,
2008). A study showed that a majority of patients with multi-
ple aphthous ulcers had underlying IBD (Letsinger et al., 2005).
The pathogenesis of aphthous stomatitis and UC is still unclear.
Studies have not been successful in proving that these ulcers are
secondary to vitamin deﬁciencies as the lesions do not typically
improve with vitamin therapy (Basu and Asquith, 1980). Apht-
hous stomatitis occurs more often in active as opposed to inactive
IBD disease: 17.1 vs. 8.6% in CD, 4.1 vs. 3% in UC, but the latter
did not reach clinical signiﬁcance (Vavricka et al., 2011). Other
studies suggest that recurrent aphthous stomatitis and symptom
onset often parallel UC disease activity (Timani and Mutasim,
2008). Treatment of aphthous stomatitis is symptomatic and con-
sists of topical anesthetics such as viscous xylocaine, steroid elixirs,
or topical steroids. Systemic steroids are used for severe or refrac-
tory cases (Basu and Asquith, 1980; Trost and McDonnell, 2005;
Timani and Mutasim, 2008; Levine and Burakoff, 2011). For sec-
ondary bacterial superinfections, topical antibiotics can be used
although they are rarely required (Levine and Burakoff, 2011).
For orofacial CD, the treatment should be directed at the local
lesion and underlying systemic disease. For more severe or refrac-
tory orofacial CD, treatment should include systemic steroids,
immunomodulators, and anti-TNF-α therapy (Quezada et al.,
2009).
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REACTIVE CUTANEOUS MANIFESTATIONS OF IBD
ERYTHEMA NODOSUM
Erythema nodosum, the most common cutaneous manifestation
of IBD, affects about 3–10% of UC and 4–15% of CD patients
(Lebwohl and Lebwohl, 1998; Georgiou et al., 2006; Timani and
Mutasim, 2008; Vavricka et al., 2011). Among patients with IBD,
EN has been found to affect 1.9% of females compared to 0.7% of
males (Turkcapar et al., 2006). A prospective study of 50 patients
FIGURE 1 | Perianal fissure in a patient with IBD. Note the longitudinal
tear pattern in the anoderm.
with EN found that only 4% were eventually diagnosed with IBD
showing that EN rarely precedes the initial diagnosis of IBD (Mert
et al., 2004; Trost and McDonnell, 2005; Weinstein et al., 2005).
EN is often associated with systemic symptoms of fevers, chills,
arthralgias, or arthritis. Arthralgias and arthritis are rare in chil-
dren, but in adults they can antedate the occurrence of EN lesions
by weeks to months (Lebwohl and Lebwohl, 1998; Berkowitz and
Lebwohl, 2000). Typical EN lesions present as painful, tender,
warm nodules (1–5 cm in diameter), and raised bluish-red sub-
cutaneous lesions or plaques located on the extensor surfaces of
extremities, predominantly on the anterior surface of the lower
extremities (Figure 3; Mir-Madjlessi et al., 1985; Evans and Pardi,
2007; Timani andMutasim, 2008;Vavricka et al., 2011). These skin
nodules are non-ulcerating, palpable, and can resemble a bruise
on the skin, but are not always easily visible (Timani andMutasim,
2008; Levine and Burakoff, 2011). EN can occur in multiple loca-
tions simultaneously and recurrence rate is approximately 20%
(Freeman, 2005).
Biopsy is generally not necessary as the diagnosis of EN may
be conﬁrmed based on the clinical presentation (Agrawal et al.,
2007). The histology of EN shows lympho-histocytic inﬁltrate of
lower dermis and focal panniculitis (Danese et al., 2005; Larsen
et al., 2010). Panniculitis is inﬂammation of the subcutaneous fat
and thus EN can occur wherever subcutaneous fat is present. The
most common site is the pretibial or shin area, but the knees,
ankles, arms, or trunk can also be affected (Levine and Burakoff,
2011). Direct immunoﬂuorescence of EN lesions reveal perivas-
cular deposits of immunoglobulins and complement, suggesting
that the pathogenesis of reactive cutaneousmanifestation of IBD is
due to the abnormal immunological response of commonantigens
between bowel bacteria and skin (Veloso, 1990; Fava and Danese,
FIGURE 2 | Aphthous stomatitis of the oral mucosa. Note the erythematous ring around the yellow to gray colored ulceration in this minor aphthous
stomatitis.
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FIGURE 3 | Erythema nodosum manifested as erythematous nodules
of the skin.These lesions are often painful and assume a bruise-like
appearance.
2011; Khor et al., 2011). EN lesions have been noted to be corre-
latedwith the underlying disease activity andworsenedwith colitis
ﬂares (Timani andMutasim,2008). Typically, the timebetweenUC
diagnosis and appearance of EN is about 5 years (Mir-Madjlessi
et al., 1985). EN in CD patients is mostly associated with colonic
involvement (Georgiou et al., 2006).
Since EN lesions mirror bowel disease activity and ﬂare up,
treatments targeting underlying IBD disease and ﬂare up always
leads to the remission of the cutaneous lesion (Orchard, 2003).
However, in situations where lesions occur during the quies-
cent phase, low doses of oral steroids can lead to rapid remis-
sion of the cutaneous lesions in most cases (Georgiou et al.,
2006). Other effective alternatives include NSAIDs, potassium
iodide, colchicine, dapsone, and immunosuppressants, such as
cyclosporine, thalidomide, etc. In recalcitrant cases, inﬂiximab has
been used with successful results (Kaufman et al., 2005). In gen-
eral, EN patients have a shorter time to remission (approximately
5weeks) than do PG patients (Tromm et al., 2001; Timani and
Mutasim, 2008).
PYODERMA GANGRENOSUM
After EN (3–8%), PG represents the second most common cuta-
neousmanifestation of IBD (1–3%), but PG is also themost severe
and debilitating (Danese et al., 2005; Georgiou et al., 2006). PG is
more common inUC (5–12%) thanCD (1–2%) and like EN, some
studies have shown a female predilection (Bernstein et al., 2001;
Trost and McDonnell, 2005). PG was ﬁrst described in 1930 by
Brunsting as necrotic ulcers containing purulent material (usually
sterile on culture) with expanding borders of erythema (Newell
and Malkinson, 1982). The non-infectious pustules and nodules
eventually expand outward and develop into painful deep ulcers
with undermined wound edges (Callen, 1998; Farhi and Wallach,
2008). The ulcer has sharply circumscribed and demarcated bor-
ders with a necrotic yellowish base. The ulcers can be single or
multiple, unilateral or bilateral, and can range in size from sev-
eral centimeters to the surface of an entire limb. Other than
the classical ulcerative form, PG may also occur in three other
forms: the pustular form (multiple painful pustules with halo),
bullous form (bullae which rapidly transform into painful ero-
sions and necrotic ulcers), and vegetans form (well-demarcated
shallow ulcer, which then gradually transform into an exophytic
lesion; Georgiou et al., 2006). PG usually occurs on the extensor
surface of the legs, but can appear anywhere on the skin, most
noticeably on the abdominal wall adjacent to a postsurgical stoma
(Lebwohl and Lebwohl, 1998). Peristomal PG lesions occur from
2weeks to 3 years after ostomy creation and they typically rapidly
evolve from small, erythematous pustules to deep ulcers within
hours to days (Cairns et al., 1994). Pathergy, the proposed mech-
anism behind this occurrence, is characterized by an exaggerated
physiological response of skin lesions that develops secondary to
local trauma and has been reported in approximately 30% of cases
of PG (Callen, 1998; Blitz and Rudikoff, 2001; Ardizzone et al.,
2008). The type of trauma can range from postsurgical wounds to
minor injuries as non-traumatic as needle sticks from venipunc-
ture (Levine and Burakoff, 2011). This is the reason that PG is
worsened with debridement and occurs more often on the leg,
around stomas, or around skin biopsy sites (Figure 4). In CD
patients, PG is often associated with colonic involvement and is
usually diagnosed approximately 10 years after the initial diag-
nosis of UC (Mir-Madjlessi et al., 1985). Compared to EN, PG
often takes a more prolonged course and approximately 35% of
patients will experience relapse of PG (Rothfuss et al., 2006). Diag-
nosis of PG is usually clinical, but skin biopsy may be necessary
for conﬁrmation. PG is classiﬁed as a type of neutrophilic der-
matosis in which the inﬂammatory inﬁltrate seen on microscopic
examination shows dense dermal neutrophilic inﬁltrates without
any evidence of infection, which was described by some as sterile
abscesses (Nischal andKhopkar, 2007; Timani andMutasim, 2008;
Cohen, 2009; Larsen et al., 2010).
The pathogenesis of PG in IBD is proposed to be an abnormal
immune response with cross-reacting autoantibodies directed at
common antigens in the bowel and skin (Crowson et al., 2003;
Feliciani et al., 2009). It is classiﬁed as one of the neutrophilic
dermatosis. Other factors such as neutrophil dysfunction, abnor-
mal T-cell response, and over-expression of pro-inﬂammatory
cytokines such as IL-8, IL-16, IL-17, and TNF-α have also been
proposed asmechanisms in the pathogenesis of PG (Feliciani et al.,
2009;Marzano et al., 2010). A case report has implicated the IL-23
and TH17 axis as being responsible for a PG lesion that subse-
quently resolvedwith amonoclonal antibody targeted at inhibiting
IL-23 expression (Guenova et al., 2011).
While EN usually correlates with IBD activity, PG correlation
with IBD activity is controversial as there are much fewer PG
cases. In a study of 14 patients with UC, there was no temporal
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FIGURE 4 | Pyoderma gangrenosum can start as small pustules that as they progress form larger and deeper ulcers. Classically, the borders of the
lesions are mucopurulent and purple. Example of pyoderma gangrenosum lesion involving the leg (A) and parastoma (B).
relationship between the onset of bowel ﬂares and the course of
PG lesions (Thornton et al., 1980). In a study of 34 IBD patients,
PG was diagnosed in 50% of UC and 75% of CDwhen underlying
bowel disease was active (Levitt et al., 1991). In a study of 986
patients hospitalized for IBD, six patients (0.6%) had PG (Men-
achem and Gotsman, 2004). Of these six patients, PG appeared
6.5 years on average after the diagnosis of IBD. The majority of
patients had active colitis at the onset of PG and half of these
patients experienced other associated EIMs, including sacroili-
itis, peripheral arthritis, and EN. However, PG does not always
respond to treatment of underlying bowel disease and response
to bowel resection is unpredictable (Levitt et al., 1991; Menachem
and Gotsman, 2004). Further studies need to be done to investi-
gate the relationship between the onset of PG and the underlying
IBD activity.
When compared to EN, PG lesions tend to be more severe
and resistant to therapy thus necessitating more aggressive ther-
apy. Furthermore, PG patients appear to beneﬁt less than EN
patients from colectomy (Goudet et al., 2001). In fact, about 30%
of patientswithPGdonot experience improvement of their lesions
with treatment of the underlying IBD (Mir-Madjlessi et al., 1985).
In general, treatment of PG includes a combination of wound
care, topical medications, antibiotics for secondary infections, and
treatment targeted at the underlying colitis (Danese et al., 2005).
Although no individual therapy is universally effective, treatment
of PG usually involves a regimen of systemic, cutaneous, and/or
intralesional medications (Timani and Mutasim, 2008; Cohen,
2009).
Local wound care includes sterile saline lavages, topical antibac-
terial creams, and hydrocolloid dressings. Topical treatments,
such as highly potent steroids with occlusive dressings, nicotine,
benzoyl peroxide, sodium cromoglycate, hydrogen peroxide, 5-
aminosalicylic acid, and tacrolimus have shown varying success
rates (Trost and McDonnell, 2005; Georgiou et al., 2006; Callen
and Jackson, 2007). Although intralesional steroid injections can
be effective in small or localized disease, the mainstay of treatment
remains systemic steroids especially for multiple lesions or gener-
alized form of PG (Georgiou et al., 2006; Timani and Mutasim,
2008). Systemic steroid therapy typically compromises of high
dose of oral prednisone around 40–120mg/day for the average
adult initially until lesional clearance, followed by a low mainte-
nance dose that is used to maintain remission (Crowson et al.,
2003). However, many alternatives exist. Assuming no concurrent
infection, mainstay therapy includes systemic corticosteroids at
dosages from0.5 to 2mg/kg/day and cyclosporine at initial dosages
of 2–5mg/kg/day (Wollina, 2002; Timani and Mutasim, 2008).
Keeping the goal trough serum levels of cyclosporine between
150 and 350 ng/ml has been shown to have good outcomes on
PG healing (Curley et al., 1985; Matis et al., 1992; Cohen, 2009;
Turner et al., 2010). Other agents including minocycline, sul-
fasalazine, azathioprine, dapsone, potassium iodide, intravenous
immunoglobulin, intravenous steroids, mycophenolate mofetil,
cyclophosphamide,methotrexate, plasmapheresis, and hyperbaric
oxygen treatment have been employed with various success rates
(Wasserteil et al., 1992; Georgiou et al., 2006; Tutrone et al., 2007;
Timani and Mutasim, 2008; Cohen, 2009). Anti-TNF-α agents
including etanercept, inﬂiximab, and adalimumab have also been
reported to treat PG lesions effectively and are used in refractory
cases of PG (McGowan et al., 2004; Brooklyn et al., 2006; Alkhouri
et al., 2009).
When treating peristomal PG lesions, about two-thirds (12/17)
of patients respond to systemic high dose steroids and local wound
care, while the rest require additional therapy or long-term med-
ical management. A study showed that no patients were success-
fully treated with stomal revision (Cairns et al., 1994). To avoid
pathergy, unnecessary surgical interventions should be avoided.
However, surgery can be considered if medical therapies are not
successful. Proper timing of the surgery to avoid active phase of
the disease and appropriate administration of immunosuppres-
sants are essential for optimal long-term wound stabilization or
remission (Wollina, 2002; Trost and McDonnell, 2005;Wittekindt
et al., 2007). For patients with extensive colitis and severe refrac-
tory PG lesions unresponsive tomedical therapy, proctocolectomy
may be considered, but PG has been reported to relapse years after
proctocolectomy (Read, 1985; Levitt et al., 1991).
PYODERMATITIS VEGETANS, PYOSTOMATITIS VEGETANS,
PYODERMATITIS–PYOSTOMATITIS VEGETANS
Pyodermatitis vegetans (PDV), a rare skin manifestation of IBD
and often regarded as one of clinical forms of PG, has histopathol-
ogy similar to pyostomatitis vegetans (discussed below) but with
treatment similar to PG (Georgiou et al., 2006). PDV occurs
mainly in skin folds such as axillary or inguinal area, but can
also be present on the trunk or extremities. These lesions are
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characterized by pustules that quickly rupture, forming erosions
with hemorrhagic ground, developing large raised (vegetating)
well-demarcated plaques with surrounding pustules (Georgiou et
al., 2006; Canpolat et al., 2011).
Pyostomatitis vegetans (PSV), a rare disorder of the oral
mucosa that is considered as the oral equivalent of PDV on cutis,
is relatively speciﬁc for IBD, particularly UC (Storwick et al., 1994;
Timani and Mutasim, 2008; Femiano et al., 2009). In contrast to
EN and PG which have been shown to have a female predilection,
there is a male predominance in PSV with a ratio ranging from
2:1 to 3:1 and the majority of cases occur in Caucasians (Femiano
et al., 2009; Ficarra et al., 2010). The pathogenesis of PSV is not
known yet, although abnormal immunological responses and/or
microbial factors are suggested (Kethu, 2006; Femiano et al., 2009;
Ficarra et al., 2010). Lesions are erythematous, thickened, and
hyperplastic folds of the buccal and labial mucosa with multi-
ple gray to yellow pustules, which progress to erosions forming
shallow, folded, and ﬁssured “snail tract” ulcers, due to degenera-
tion, ulceration, and suppuration of vegetating pustules (Femiano
et al., 2009). They often manifest before the diagnosis of IBD
(Hansen et al., 1983; Femiano et al., 2009). Lesions also occur
at labial attached gingiva, soft and hard palate, oral vestibule, and
tonsillar regions. They usually spare the tongue and ﬂoor of the
mouth (Femiano et al., 2009). Symptoms of burning and painmay
be present (Ficarra et al., 2010). Other than oral cavity, mucosal
membranes at the vaginal, nasal, and rarely periocular areas can
also be affected (Femiano et al., 2009). Peripheral eosinophilia has
been found in most cases reported and maybe a valuable aid for
the diagnosis of PV (Femiano et al., 2009). Histopathologically,
PSV is characterized by epithelial acanthosis and superﬁcial ulcer-
ation with intraepithelial and/or subepithelial micro abscesses
containing numerous eosinophils and neutrophils with underly-
ing connective tissues containing dense lymphocytic and plasma
cell inﬁltrate (Femiano et al., 2009; Ficarra et al., 2010).
Pyodermatitis vegetans was ﬁrst reported by Hallopeau (1898)
when he described two patients with unusual pustular dermatosis
and oral lesions for which he named pyodermite vegetans (Hallo-
peau, 1898). McCarthy (1949) proposed the term “pyostomatitis
vegetans” after he observed similar lesions isolated in the oral cav-
ity (McCarthy, 1949; Femiano et al., 2009). Recently these two
entities are considered to be variants of the same disease termed
pyodermatitis–pyostomatitis vegetans (PPV; Ficarra et al., 2010).
PDV and PSV (or together as a group PPV) are rare cutaneous
manifestation of IBD (Storwick et al., 1994; Femiano et al., 2009).
In general,bowel disease antedate oral involvement by several years
(Leibovitch et al., 2005). The rash of PPV has been reported to cor-
relate with underlying bowel disease activity (Ayangco et al., 2002;
Kitayama et al., 2010). The pathogenesis of PSV, PDV, or PPV is
not clear, but has been hypothesized to be due to aberrant immune
responses in IBD to cross-reacting antigens in the skin and bowel
resulting inmucocutaneousmanifestations (Femiano et al., 2009).
Employing immunosuppressants and systemic steroids to treat
PSV has variable efﬁcacy for treating symptoms and maintaining
remission (Timani and Mutasim, 2008). Local therapies includ-
ing hydrogen peroxide, topical steroids, and antibacterial mouth-
washes are usually not effective in controlling disease activity. A
case report demonstrated successful PSV remission with topical
ﬂuocinonide gel, but the patient relapsed and ultimately required
total colectomy to achieve andmaintain remission (Calobrisi et al.,
1995; Femiano et al., 2009). In fact, subtotal colectomy in a patient
with UC resulted in the development of PPV and relapse of bowel
disease 5 years after surgery (Kitayama et al., 2010).
NEUTROPHILIC DERMATOSES
Neutrophilic dermatoses include Sweet’s syndrome (SS) and
bowel-associated dermatosis–arthritis syndrome (BADAS). SS,
ﬁrst described by R. D. Sweet and named after him, is character-
ized by the abrupt onset of tender and red to purple inﬂammatory
nodules or papules that coalesce to form plaques, affecting the
upper limbs, face, or neck. In addition to painful and edema-
tous nodules and plaques, vesicles, bullae, or pustules may also
be present (Georgiou et al., 2006; Nischal and Khopkar, 2007).
Patients with colonic disease and females between the ages of 30
and 50 have increased risk for developing SS (Ardizzone et al.,
2008; Timani and Mutasim, 2008). SS is also known as acute neu-
trophilic dermatosis as it is typically accompanied by fever and
peripheral neutrophilia with >70% neutrophils while cutaneous
lesions usually show dense aseptic neutrophilic inﬁltration (Geor-
giou et al., 2006). These lesions are tender and non-pruritic in
nature, but can be difﬁcult to distinguish fromENwhen they affect
the lower extremities (Guhl and Garcia-Diez, 2008). Skin biopsy,
which shows neutrophilic inﬁltrates in the reticular dermis, can be
helpful in reaching a diagnosis when there is doubt (Kemmett and
Hunter, 1990; Georgiou et al., 2006; Timani and Mutasim, 2008;
Cohen, 2009). Patients may also experience fatigue, headache, and
other non-speciﬁc constitutional symptoms. SS can affect extra-
cutaneous organ systems including, but are not limited to the
musculoskeletal, ocular, hepatic, pulmonary, and renal systems
(Cohen et al., 1988).
Although the pathogenesis is unclear, SS usually develops as a
reactive response to some type of underlying systemic disease, such
as infection, malignancy, medications, or IBD (Vij et al., 2010). In
fact, studies have shown that patients with SS have some type of
underlying systemic disease in 50% of cases and an underlying
malignancy in 20% of cases (Kemmett and Hunter, 1990; Souissi
et al., 2007). UC and CD are the most common systemic diseases
associated with SS (Timani and Mutasim, 2008). SS is associated
with active bowel disease (67–80%; Georgiou et al., 2006; Ardiz-
zone et al., 2008). The onset of symptoms from SS usually occur
after the initial diagnosis of IBD, but may antedate the onset of
IBD (21%) and has also been reported to occur 3months after
proctocolectomy in patients with UC (Darvay, 1996; Ardizzone
et al., 2008). Similar to other reactive manifestations of IBD, the
pathogenesis of SS has beenhypothesized to be related to an altered
immune response to common antigens in the skin and gut bac-
teria (Ali and Duerksen, 2008). Furthermore, ANCA and G-CSF
or other cytokines have been proposed to play a pathogenetic role
in activation, maturation, and chemotaxis of neutrophils in SS
(Diaz-Peromingo et al., 2001; Cohen and Kurzrock, 2003).
First line treatment of SS involves systemic steroids and studies
have shown marked symptom improvement with a 6week steroid
course (Cohen et al., 1988; Souissi et al., 2007).When dealing with
localized disease, topical, or intralesional steroids are sometimes
used with good effects (Timani and Mutasim, 2008). However,
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recurrence of SS is relatively common with as many as 1/3 of
patients re-experiencing symptoms despite treatment (Kemmett
and Hunter, 1990). Skin lesions that have not been treated have
been documented to heal on their own, but can leave behind
scars (Kemmett and Hunter, 1990; Timani and Mutasim, 2008).
Other ﬁrst line options for treatment include colchicine and potas-
sium iodide. Other agents such as indomethacin and clofazimine
can be used if ﬁrst line agents are ineffective or cannot be toler-
ated. (Cohen and Kurzrock, 2002; Cohen, 2009). Treatments with
immunosuppressants and anti-TNF-α have been reported to be
successful in SS (Ali and Duerksen, 2008; Cohen, 2009; Larsen
et al., 2010).
The BADAS, previously named as bowel bypass syndrome as
it was originally reported to occur in up to 20% of patients after
laparoscopic jejuno-ileal bypass surgery for obesity, can occur as a
complication after various intestinal surgeries, in patients with
diverticulitis or appendicitis, and in patients with IBD (Geor-
giou et al., 2006; Ashok and Kiely, 2007; Patton et al., 2009; Tu
et al., 2011). The clinical characteristics of BADAS syndrome are
recurrent episodes of fever, malaise, abdominal pain, arthritis,
and polyarthralgias of the upper extremities involving the asym-
metric large joints and interphalangeal joints of the ﬁngers with
accompanying tenosynovitis, and by the appearance of character-
istic cutaneous lesions (Ashok and Kiely, 2007). These cutaneous
lesions consist of erythematous macules (3–10mm in diameter),
developing into edematous and painful papules with central asep-
tic vesicles or pustules (2–4mm in diameter) over the subsequent
1–2 days, which are located on the upper chest and arms (usually
on the deltoidmuscle region) andEN-like lesions in the legs. These
maculopapular rashes occur in crops, resolve within 1–2weeks
without leaving scars and can recur every 1–6weeks. These cuta-
neous lesions are temporally dependent on IBD activity (Ashok
and Kiely, 2007; Patton et al., 2009).
The histology of BADAS is characterized by perivascular neu-
trophilic, mononuclear, and eosinophilic (depending on the stage
of the lesions) inﬁltrate with dermal edema, intraepidermal pus-
tules, minimal alterations of the walls of capillaries and venules
without the features of leukocytoclastic vasculitis or ﬁbrinoid
necrosis (Georgiou et al., 2006; Nischal and Khopkar, 2007). Sim-
ilar to PG and SS, BADAS has been classiﬁed in the spectrum
of aseptic neutrophilic dermatoses with histopathology showing
dense neutrophil inﬁltration and no destruction of vessel walls
(Nischal and Khopkar, 2007; Patton et al., 2009). By immuno-
ﬂuorescence staining, the deposition of immunoglobulins and
complement has frequently beenobserved at the dermo-epidermal
junction. The pathogenesis of BADAS is hypothesized to be due to
immune complex-mediated vessel damage, followed by increased
migration and accumulation of neutrophils in the perivascular
area (Jorizzo et al., 1984). The circulating immune complexes
are believed to form due to an immunological response against
antigenic bacterial peptidoglycans in the gut, with subsequent
deposition in the skin and joints (Jorizzo et al., 1984; Nischal and
Khopkar, 2007; Patton et al., 2009). It is theorized that overgrowth
of bacteria, such as seen in active IBD, diverticulitis, appendici-
tis, blind loop after bypass surgery, or in the inﬂamed bowel
segment after surgery, result in inﬂammation, and the forma-
tion of abnormal immunological responses to bacterial antigens
especially peptidoglycans (Georgiou et al., 2006; Patton et al.,
2009). Similar pathophysiology is also thought to involve the cuta-
neous manifestations of EN, PG, and SS (Georgiou et al., 2006;
Nischal and Khopkar, 2007).
The management of the BADAS includes the treatment of
the underlying bowel disorder and the administration of sys-
temic steroids and antibiotics for inhibition of bacterial over-
growth (tetracycline, metronidazole, ciproﬂoxacin), although the
response to these antibiotics are inconsistent (Georgiou et al., 2006;
Patton et al., 2009). NSAIDsmay be used to alleviate arthralgias or
arthritis, but the potential toxicity of NSAIDs on IBD shouldmake
the decision to use NSAIDs based on weighing the risk-beneﬁt
ratio for each individual patient (Singh et al., 2009). Other drugs
such as colchicine, dapsone, and sulfasalazine have been tried with
variable successful rates (Georgiou et al., 2006).
LEUKOCYTOCLASTIC VASCULITIS
Leukocytoclastic vasculitis, one of the rare cutaneous manifes-
tation of IBD, is characterized histopathologically by neutrophil
inﬁltration and nuclear debris of inﬂamed postcapillary venules
with endothelial enlargement and ﬁbrinoid necrosis (Akbulut
et al., 2008). The skin presentation ranges from palpable purpura
(mediated by deposition of immune complexes in postcapillary
venules) on the lower extremities and ankles to necrotic ulcers
(Tsiamoulos et al., 2008). Similar to other reactive cutaneousman-
ifestations of IBD, the pathogenesis of leukocytoclastic vasculitis
with histology showing hypersensitivity vasculitis of small vessels
is proposed to be circulating immune complexes (Mackel and Jor-
don, 1982; Iannone et al., 2003; Akbulut et al., 2008; Tsiamoulos
et al., 2008). In CD, leukocytoclastic vasculitis occurs not only
during the onset of bowel disease, but also during periods of exac-
erbation. On the other hand, in UC, leukocytoclastic vasculitis
most commonly precede the onset of bowel disease with a lag-
ging period ranging from 1month to 2 years (Iannone et al., 2003;
Akbulut et al., 2008; Tsiamoulos et al., 2008). In most cases of
leukocytoclastic vasculitis, treating the underlying IBD results in
resolution of the lesions (Akbulut et al., 2008; Tsiamoulos et al.,
2008).
CUTANEOUS DISORDERS OR DERMATOSIS ASSOCIATED
WITH IBD
These disorders include hidradenitis suppurativa, phlebitis, ery-
thema multiforme, urticaria, lichen planus, secondary amyloido-
sis, and various autoimmune skin disorders, such as acquired
epidermolysis bullosa (blistering lesions of the knees, elbows,
hands, and feet), bullous pemphigoid, linear IgA bullous der-
matosis, vitiligo, and psoriasis (Georgiou et al., 2006; Levine and
Burakoff, 2011). Rarely has IBD been reported to be associated
with skin neoplasm such as Bowen’s disease and squamous cell
carcinoma,which require surgical excision (Georgiou et al., 2006).
Acquired epidermolysis bullosa or epidermolysis bullosa
acquisita (EBA) is characterized by autoantibodies to type VII
collagen (detected in both the skin and colon of normal individ-
uals), which was also detected in 13/19 CD and 4/31 UC patients
(Chen et al., 2002; Hoffmann and Kruis, 2004). In fact, EBA has
been reported to be most frequently (25%) associated with CD
(Hoffmann and Kruis, 2004). This ﬁnding suggests that chronic
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inﬂammation in the intestine predisposed IBD patients to develop
autoantibodies against type VII collagen in the gut, which in turn
attacks the skin at the dermal–epidermal junction resulting in
the blistering skin lesions seen in EBA (Hundorfean et al., 2010).
Future research is needed to provide more insight in this hypoth-
esis. Compared to an incidence of 0.3% of vitiligo in the normal
population, the incidence of vitiligo is higher in CD (0.5%) and
UC (1.1%; Pashankar et al., 1999). The pathogenesis of vitiligo in
IBD has been proposed to be autoimmune or genetic HLA linkage
in nature (Pashankar et al., 1999; Quan et al., 2010). Secondary
amyloidosis is rare in IBD and occurs as a systemic response to
chronic inﬂammation. The systemic amyloidosis in IBD is type
AA amyloidosis and is more common in CD (0.9%) than UC
(0.07%) most likely as a result of a higher degree of inﬂammation
in CD (Sattianayagam et al., 2009).
The most frequently associated cutaneous disease is psoriasis
which occurs in 7–11% of the IBD population compared to 1–2%
of general population (Danese et al., 2005). In one study, psoriasis
was found to be more prevalent in CD (11.2%) than UC (5.7%;
Yates et al., 1982;Vavricka et al., 2011). The association of IBDwith
psoriasis is believed to be both genetically and immunologically
related (Georgiou et al., 2006). In a recent study of 146 patients
with both IBD and psoriasis compared to a control of 146 patients
with only psoriasis, it was found that patients with both IBD and
psoriasis had signiﬁcantly higher rates of autoimmune thyroidi-
tis (6.8 vs.2.1%), hepatitis (6.2 vs. 0.7%), and diabetes (26.7 vs.
11.0%; Binus et al., 2011). Individuals with both IBD and psoriasis
also had signiﬁcantly higher CRPs, ESRs, and sero-negative arthri-
tis (41.1%) compared to individuals with only psoriasis. Certain
gene loci on chromosomes 3, 4, 6, and 16 are associated with both
CD and psoriasis (Georgiou et al., 2006). A recent study showed
that a striking overlap of loci between diseases of CD, UC, pso-
riasis, ankylosing spondylitis, and primary sclerosing cholangitis
(Cho and Brant, 2011). These studies suggest that genetic predis-
positions or HLA linkages for certain speciﬁc immune response
patterns and common inﬂammatory pathwaysmay play an impor-
tant role in the association of these diseases (Georgiou et al., 2006;
Binus et al., 2011).
SECONDARY CUTANEOUS MANIFESTATIONS DUE TO
COMPLICATIONS OF IBD OR ITS TREATMENTS
MANIFESTATIONS SECONDARY TO MALNUTRITION AND
MALABSORPTION
Skinmanifestations of IBD secondary tomalnutrition and/ormal-
absorption include the acquired form of acrodermatitis entero-
pathica (zinc deﬁciency), pellagra (niacin deﬁciency), scurvy (vit-
amin C deﬁciency), purpura (vitamin C and K deﬁciency), stom-
atitis/glossitis/angular cheilitis (vitamin B deﬁciency), xeroderma,
or dry skin and unspeciﬁed eczema (essential fatty acid deﬁ-
ciency), hair and nail abnormalities (malabsorption of amino acid
and protein; Trost and McDonnell, 2005; Georgiou et al., 2006;
O’Sullivan and O’Morain, 2006). The acquired form of acroder-
matitis enteropathica, due to zinc deﬁciency, is the most common
nutritional-deﬁcient cutaneous manifestation of IBD and more
common in CD than UC (Dronﬁeld et al., 1977; McClain et al.,
1980; Danese et al., 2005). The skin lesions present as psoriasis
involving an erythematous patch and plaque, which may evolve
into crusted vesicles, bullae, or pustules. The lesions occur fre-
quently around the mouth, anus, limbs, ﬁngers, and scalp (Danese
et al., 2005; von Felbert and Hunziker, 2010). Adequate supple-
mentation of the deﬁcient nutrients or vitamins is the treatment
of choice. For example, acrodermatitis enteropathica is treated
with zinc sulfate 220mg/day (Danese et al., 2005; Georgiou et al.,
2006).
SECONDARY CUTANEOUS MANIFESTATIONS DUE TO ADVERSE
EFFECTS OF IBD TREATMENT
Skinmanifestations fromadverse effects can result in a broad range
of secondary cutaneous manifestations, such as drug eruptions,
urticaria, angioedema, hair loss, lichen planus, erythema multi-
forme, bullous dermatosis/reaction, Stevens–Johnson syndrome,
acne, psoriasis and so on (Georgiou et al., 2006; Fiorino et al.,
2009). The following are examples of drugs used in IBD treat-
ments that can cause secondary cutaneous complications: 5-ASA,
metronidazole, ciproﬂoxacin, azathioprine, 6-MP, methotrexate,
cyclosporine, steroids, anti-TNF-α agents, etc. (Georgiou et al.,
2006; Passarini et al., 2007).
Anti-TNF-α agents have been used successfully in the treatment
of IBD and psoriasis, but when treating IBD, anti-TNF-α agents
such as inﬂiximab and adalimumab can paradoxically induce pso-
riasis lesions after the third or fourth infusion (Passarini et al.,
2007; Fiorino et al., 2009). The psoriasis lesions regressed after
withdrawing the anti-TNF-α agents in 16 out of 17 patients (Fior-
ino et al., 2009). Although there have only been 18 reported cases
of anti-TNF α induced psoriasis in the IBD population, but clin-
icians should still be aware of this potential side effect (Fiorino
et al., 2009). It has been suggested that inhibition of TNF-α induces
over-expression of cutaneous IFN-α which then causes predispo-
sition to psoriasis (Iborra et al., 2011). The treatment of psoriasis
induced by anti-TNF-α agents is cessation of the offending agents
and topical steroid therapy (Iborra et al., 2011).
CONCLUSION
The most common cutaneous manifestations of IBD are EN and
PG (Levine and Burakoff, 2011). All IBD patients should be closely
examined for skin manifestations as some skin lesions may be
related to IBD activity. Manifestation of one EIM increases the
risk of developing additional EIMs, and all EIMs affect both mor-
bidity and mortality in IBD (Monsen et al., 1990; Das, 1999;
Vavricka et al., 2011). Similar to other EIMs of IBD, skin lesions
may postdate, occur with, or antedate the onset of the underlying
disease process (Apgar, 1991). Since dermatological manifesta-
tions can precede bowel disease or bowel exacerbation, idiopathic
skin lesions such as EN, PG, recurrent multiple aphthous stom-
atitis, or PPV should alert clinicians to evaluate the possibility
of underlying IBD so that early diagnosis and intervention with
the appropriate therapy can be initiated (Levine and Burakoff,
2011).
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